A Rheumatoid Arthritis Study to Assess Early Response to Abatacept+MTX as Defined by Improvement of Synovitis Measures by Power Doppler Ultrasonography
Completed · Phase 3 · NCT00767325
Conditions: Rheumatoid Arthritis
At a glance
- Research payments reported, 2025
- $653,905
- U.S. investigators named
- 1
- Sites paid
- 1
- Planned or actual enrollment
- 104
About the trial
- Sponsor
- Bristol-Myers Squibb
- Tested
- Abatacept (drug), Methotrexate (drug)
- Dates
- Started 2008-12; completion 2011-10
- Results posted
- Yes
The purpose of the study is to assess early signs of response to abatacept+methotrexate in metacarpophalangeal joints in both hands using power Doppler ultrasonography in patients with active rheumatoid arthritis.
From ClinicalTrials.gov, last updated 2013-07-02. Full record, eligibility and contacts (opens in a new tab)
Industry funding
E.r. Squibb & Sons, L.l.c. reported $653,905 in research payments for this study in 2025 (1 payments).
Products named: Orencia
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.